Eventide Funds are a product of  Eventide Asset Management  

You are now leaving the Eventide Funds website and entering the Eventide Asset Management website.

Continue to Eventide Asset ManagementCancel

Our Products (Thru 9/2018)

Our Products (Thru 9/2018)

The goal of Eventide Mutual Funds is to maintain market outperformance by investing in companies that we believe excel at creating value, operate with integrity, and profit from ethical and sustainable activities. We invite individuals, advisors, and institutions to learn more about our products below, including performance, holdings, prospectus, and other details.

Objective

Seeks to provide long-term capital appreciation

About the Fund

A diversified, equity mutual fund representing our “best ideas” that seeks to provide long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Investment Process

There is no guarantee that the Adviser’s Investment Process will produce the desired results. All investments involve risks, including possible loss of capital.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

David Barksdale has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and asset allocation. He holds a bachelor’s degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Eventide Gilead Fund Portfolio Composition

2. Market cap definitions are now based on those used by Morningstar, where Giant Cap are those companies that account for the top 40% of capitalization, Large Cap is the next 30%, Mid Cap is the next 20%, Small Cap is the next 7%, and Micro Cap is the last 3%. Fact sheets dated before June 30, 2018 defined $10 billion or greater as Large Cap; greater than $1 billion was Mid Cap; and less than $1 billion was Small Cap. The definition was updated to account for industry changes, and should not imply a strategic change in the management of the fund’s portfolio.

3. Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year ending on June 30th. A higher portfolio turnover may indicate higher transaction costs for the fund, and may result in higher taxes for investors. The range shows the highest and lowest turnover ratio reported in the prospectuses during the last three years.

4. The fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time and should not be considered investment advice.

As of June 30, 2018:

Fund Performance

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses, or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund toll free at 1-877-771-EVEN (3836).

Eventide Gilead Fund’s Class N expenses: Total Expenses 1.41%.

2. These charts compare the Eventide Gilead Fund Class N’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of $10,000 Chart assumes Class N’s inception date of July 8, 2008 for the indices.

3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

4. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the indices listed.

5. Performance figures for periods greater than 1 year are annualized. The fund‘s share classes have different inception dates. Class N has an inception date of July 8, 2008. Class A and Class C have an inception date of October 28, 2009. Class I has an inception date of February 2, 2010. The indices assume an inception date of July 8, 2008.

As of June 30, 2018:

EGF-market-risk

5. Source: © Morningstar, Inc. (2018). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

6. Annualized since inception market risk details assume inception date of August 1, 2008 and not Class N’s actual inception date of July 8, 2008, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

  • XPO Logistics Inc (4.14%) Global provider of transportation and logistics solutions
  • Wayfair Inc (3.90%) Online sales of furniture and home decor
  • Ascendis Pharma A/S (3.48%) Rare-disease focused biopharmaceuticals
  • Lowe’s Cos Inc (2.83%) More than 2,390 home improvement stores in the U.S., Canada, and Mexico
  • Splunk Inc (2.35%) Web based application to automate operational intelligence and big data interpretation
  • HubSpot Inc (2.30%) Inbound sales and marketing platform
  • Palo Alto Networks Inc (2.24%) Provides integrated cloud and network security solutions
  • Macquarie Infrastructure Corp (2.17%) Aircraft services, liquid storage and marine terminals
  • Instructure Inc (2.10%) Online education technology
  • Lam Research Corp (2.06%) Semiconductor wafer fabrication equipment

Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary, and presentation for the Eventide Gilead Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

  • Equity mutual fund investing in healthcare and life sciences
  • Uses bottom-up fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products.
  • Under normal market conditions, the Fund will invest at least 80 percent of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Portfolio Composition

2. Market cap definitions are now based on those used by Morningstar, where Giant Cap are those companies that account for the top 40% of capitalization, Large Cap is the next 30%, Mid Cap is the next 20%, Small Cap is the next 7%, and Micro Cap is the last 3%. Fact sheets dated before June 30, 2018 defined $10 billion or greater as Large Cap; greater than $1 billion was Mid Cap; and less than $1 billion was Small Cap. The definition was updated to account for industry changes, and should not imply a strategic change in the management of the Fund’s portfolio.

3. Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year ending on June 30th. A higher portfolio turnover may indicate higher transaction costs for the Fund, and may result in higher taxes for investors. The range shows the highest and lowest turnover ratio reported in the prospectuses during the last three years.

4. Industry Allocation is subject to change at any time, and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

EHLSF-performance

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. To obtain the most recent month-end performance information and a current Eventide Healthcare & Life Sciences Fund prospectus please call the fund toll free at 1-877-771-EVEN (3836).

Eventide Healthcare & Life Sciences Fund’s Class N expenses: Net Expenses 1.55%.

2. These charts compare the Eventide Healthcare & Life Sciences Fund Class N’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of $10,000 chart assumes the fund’s inception date of December 27, 2012 for the indices.

3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

4. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product available for purchase. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The volatility of the indices may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the indices listed.

5. Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of December 27, 2012.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Market Risk

5. Source: © Morningstar, Inc. (2018). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

6. Annualized since inception market risk details assume inception date of January 1, 2013 and not fund’s actual inception date of December 27, 2012, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

  • Sarepta Therapeutics Inc (4.90%) Precision genetic medicines to treat rare neuromuscular diseases
  • Ascendis Pharma A/S (3.77%) Rare-disease focused biopharmaceuticals
  • Zogenix Inc (3.07%) Developing therapies for uncontrolled seizures
  • Collegium Pharmaceutical Inc (2.99%) Prescription and over-the-counter pharmaceuticals
  • Sage Therapeutics Inc (2.82%) Develops treatments for central nervous system disorders.
  • Myovant Sciences Ltd (2.71%) Clinical-stage therapies for women’s health diseases
  • uniQure NV (2.61%) Developing gene therapies in hemophilia, Huntington’s disease, and cardiovascular disease
  • AVROBIO Inc. (2.57%) Developing gene therapies for rare and orphan diseases
  • Immunomedics Inc (2.41%) Novel antibody therapeutics for the treatment of cancer, especially breast cancer
  • Loxo Oncology Inc (2.40%) Develops small molecule genetically defined cancer drugs.

Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary and presentation for the Eventide Healthcare & Life Sciences Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Investment Objective: The Eventide Multi-Asset Income Fund seeks current income while maintaining the potential for capital appreciation. The Fund has significant flexibility to achieve its investment objective by primarily investing in a broad universe of income-producing securities. These securities include debt and equity securities of companies in the U.S. and other markets around the world.

These securities may include but are not limited to common stocks, real estate investment trusts (REITs), business development companies, yieldcos, master limited partnerships (MLPs), preferred stocks, corporate bonds, government agency bonds, certificates of deposit, municipal bonds, inflation-linked bonds, mortgage-backed securities, options, exchange traded notes, exchange traded funds and other investment companies (including mutual funds and closed-end funds). The Fund may invest up to 15% of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid.

Investment Strategy: Eventide uses a two step process to select securities for the Fund. The investment process begins with a “top down” analysis to select a variety of asset classes that are believed to offer the best opportunity for current income and/or capital appreciation. Factors considered include an assessment of current income opportunities, the potential for income growth, valuation, capital appreciation potential and/or portfolio risk/return attributes. The second step is a fundamental “bottom-up” analysis to evaluate specific securities for inclusion in the portfolio. Eventide favors securities that, in its opinion, are attractively valued, provide attractive current income, provide income appreciation potential, provide capital appreciation potential, and/or help to reduce overall portfolio volatility.

Sub-Adviser: Eventide has retained Boyd Watterson Asset Management, LLC to manage some or all of the Fund’s assets allocated for investment in the intermediate-term bond portion of the portfolio. In selecting securities for investment by the Fund, Boyd Watterson employs a top-down approach to determine how to structure the bond allocation taking in to consideration duration, maturity, and sector allocation. Boyd Watterson then initiates a process of security analysis based on several factors including, but not limited to, economic trends, industry assessments and issuer specific credit fundamentals.

Values-based investing: Eventide aims to analyze each potential investment’s ability to operate with integrity and create value for customers, employees, the environment, and other key stakeholders. While few companies may reach these ideals in every area of their business, these principles articulate the Advisor’s ideal characteristics of good corporate behavior. The Advisor makes no guarantee that fund investments will meet any or all of these characteristics.

Learn more about the Eventide Multi-Asset Income Fund in this presentation.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Martin Wildy, CFA serves on Eventide’s portfolio management team as the lead portfolio manager for the Eventide Multi-Asset Income Fund. Prior to joining Eventide in 2015, Mr. Wildy was a senior portfolio manager with Aris Wealth Services, a division of AssetMark, Inc. where he worked since 2006. Mr. Wildy served on Aris’s Investment Committee and was responsible for investment decisions that impacted a number of the firm’s investment strategies, including Aris’ Income Builder and values-based portfolios. In his role, Mr. Wildy’s responsibilities included developing capital market assumptions, asset allocation decisions, investment due diligence, and portfolio management. Mr. Wildy holds a bachelor’s degree from the Pennsylvania State University in Finance and has held the Chartered Financial Analyst (CFA) designation since 2003.

David M. Dirk, CFA serves as the Portfolio Manager for some or all of the fund’s intermediate-term bond portion. Mr. Dirk has been co-director of fixed Income for the fund’s sub-advisor, Boyd Watterson, with responsibility of directing all portfolio management and trading activity since 2011. This includes the implementation, execution, and evaluation of all strategies across Boyd Watterson’s suite of fixed income products. Mr. Dirk joined Duff & Phelps, predecessor to Boyd Watterson Asset Management, in 1996. David holds a CFA Charter from CFA Institute, an MBA from Case Western Resverve University, and a BA from Baldwin-Wallace College. He is also a member of the CFA Society of Cleveland and CFA Institute.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Portfolio Composition
4. Fund allocation percentages are subject to change at any time, and should not be considered investment advice.

5. Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year ending on June 30th. A higher portfolio turnover may indicate higher transaction costs for the fund and may result in higher taxes for investors. The range shows the highest and lowest turnover ratio reported in the prospectuses during the last two years.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Performance

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses, or sales charges. To obtain the most recent month-end performance information and a current Eventide Multi-Asset Income Fund prospectus please call the fund toll free at 1-877-771-EVEN (3836).

Eventide Multi-Asset Income Fund Class N expenses: Net Expenses 1.46%.

2. The numbers shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

3. The table displays the Eventide Multi-Asset Income Fund Class N’s dividend and capital gains distributions for the periods shown. The distributions will differ for other fund classes, based upon fees and commissions. The total distribution may represent dividend and interest income, capital gains, and/or return of capital. Shareholders should not assume that the source of a distribution from the fund is net profit. As of 6/30/18, the distributions represented contain no return of capital. The characterization of income is an estimate only and subject to change for tax purposes.
4. NAV presented is as of the date of the respective quarter end.
5. Source: Morningstar, Inc.
6. Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of July 15, 2015.
7. The Multi-Asset Income Blend is a proprietary Eventide benchmark based on 60% MSCI All Country World Index (Net), 40% Bloomberg Barclays US Aggregate Bond Index © at inception, rebalanced monthly. The MSCI All-Country World Index (Net) captures large and mid cap representation across 23 developed markets and 23 emerging markets. The volatility of the indices may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the indices listed.

As of June 30, 2018:

Market Risk

6. Source: © Morningstar, Inc. (2018). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

7. Since inception market risk details assume inception date of 1 August 2015 and not Class N’s actual inception date of 15 July 2015, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

  • NextEra Energy Partners LP (2.64%) Contracted clean energy projects including wind and solar
  • Brookfield Renewable Partners LP (2.41%) Wind, hydropower facilities in Europe and the Americas
  • First Hawaiian Inc (2.09%) Hawaii’s oldest and largest bank, offering diversified banking services
  • Atlantica Yield plc (1.98%) Renewable energy, power generation, and electric transmission
  • Schneider Electric SE (1.92%) Global Specialist in energy management and automation
  • Spectra Energy Partners LP (1.89%) Energy infrastructure for transport and storage of natural gas
  • Macquarie Infrastructure Corp (1.88%) Aircraft services, liquid storage and marine terminals
  • Munich Re (1.86%) Germany-based global reinsurance and insurance
  • ABB Ltd (1.84%) Power systems, automation, and robotics for industrial applications
  • Digital Realty Trust Inc (1.79%) Owns and operates technology-focused real estate such as data centers

Does not include Money Market Funds. Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary and presentation for the Eventide Multi-Asset Income Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

FUND OBJECTIVE

Seeks to provide dividend income and long-term capital appreciation with a secondary objective of dividend growth.

ABOUT THE FUND

A globally diversified equity fund representing our “best ideas” approach to dividend-paying stocks.

FUND DISTINCTIVES

Globally Invested. Invests globally across industry sectors and market capitalizations through both traditional and non- traditional equity income categories.

Dividend Focused. Seeks to invest in companies that pay attractive dividends, demonstrate the ability to grow dividends in the future, and offer long-term capital appreciation potential.

Creating a Better World. Focused on identifying and investing in companies capable of sustaining profitability and growth by serving well the needs of customers, employees, suppliers, communities, the environment, and society broadly.

Learn more about the Eventide Global Dividend Opportunities Fund in this overview.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Martin Wildy, CFA serves on Eventide’s portfolio management team as the lead portfolio manager for the Eventide Global Dividend Opportunities Fund. Prior to joining Eventide in 2015, Mr. Wildy was a senior portfolio manager with Aris Wealth Services, a division of AssetMark, Inc. where he worked since 2006. Mr. Wildy served on Aris’s Investment Committee and was responsible for investment decisions that impacted a number of the firm’s investment strategies, including Aris’ Income Builder and values-based portfolios. In his role, Mr. Wildy’s responsibilities included developing capital market assumptions, asset allocation decisions, investment due diligence, and portfolio management. Mr. Wildy holds a bachelor’s degree from the Pennsylvania State University in Finance and has held the Chartered Financial Analyst (CFA) designation since 2003.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Portfolio Composition

4. Under normal conditions, at least 40% of the fund’s assets will be in securities of issuers domiciled in at least 3 countries outside of the United States. Domicile percentages can change at any time and should not be considered investment advice.

5. Fund allocation percentages are subject to change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

Performance

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Global Dividend Opportunities Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Global Dividend Opportunities Fund Class N expenses: Net Expenses 1.17%.

2. The numbers shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

3. The chart displays the Eventide Global Dividend Opportunities Fund Class N’s dividend and capital gains distributions for the periods shown. The distributions will differ for other fund classes, based upon fees and commissions. The total distribution may represent dividend and interest income, capital gains, and/or return of capital. Shareholders should not assume that the source of a distribution from the fund is net profit. As of 6/30/2018, the distributions represented contain no return of capital. The characterization of income is an estimate only and subject to change for tax purposes.

4. NAV presented is as of the date of the respective distribution.

5. Source: Morningstar

6. Performance figures for periods greater than 1 year will be annualized. Since inception returns assume an inception date of 9/29/2017.

7. The MSCI All Country World Index is a free float adjusted market capitalization weighted index that is designed to measure the equity market performance of developed and emerging markets and consists of 46 country indexes comprising 23 developed and 23 emerging market country indexes. The volatility of the index may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the index listed.

As of June 30, 2018:

Market Risk

6. The performance and risk factor comparisons are made against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard deviation of return measures the amount of variation in historical performance from period to period.

7. Since inception market risk details assume inception date of 10/01/2017 and not Class N’s actual inception date of 9/29/2017, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2018:

  • Atlantica Yield plc (3.26%) Diversified portfolio of renewable energy, power generation, and electric transmission
  • Brookfield Renewable Partners LP (3.23%) Wind, hydropower facilities in Europe and the Americas
  • NextEra Energy Partners LP (3.14%) Owns, operates, and acquires contracted clean energy projects including wind and solar
  • Taiwan Semiconductor Manufacturing Co Ltd (3.11%) Global semiconductor manufacturer
  • Crown Castle International Corp 6.875000 (3.06%) Wireless and broadband infrastructure
  • ABB Ltd (3.03%) Power systems, automation, and robotics for industrial applications
  • Eaton Corp PLC (3.02%) Globally diversified provider of electrical, hydraulic, and power management products
  • First Hawaiian Inc (2.99%) Hawaii’s oldest and largest bank, offering diversified banking services
  • Honda Motor Co Ltd (2.89%) Multi-national manufacturing conglomerate
  • Magna International Inc (2.61%) Developing and building automotive systems

Does not include Money Market Funds. Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary, and presentation for the Eventide Global Dividend Opportunities Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds’ ethical values screening criteria could cause them to under-perform similar funds that do not have such screening criteria.

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.

4309-NLD-4-25-2016